Erratum: Error in text: Use of medications of questionable benefit in advanced dementia (JAMA Internal Medicine (2014) 10.1001/jamainternmed.2014.4103);Use of medications of questionable benefit in advanced dementia

JAMA Internal Medicine

Volumn 174, Issue 11, 2014, Pages 1763-1771

  Tjia, Jennifer ^a   Briesacher, Becky A ^a   Peterson, Daniel ^b   Liu, Qin ^c   Andrade, Susan E ^b   Mitchell, Susan L ^d  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Hebrew Senior Life   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CHOLINESTERASE INHIBITOR; HORMONE ANTAGONIST; IMMUNOMODULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEMANTINE; SEX HORMONE;

ACTIVITY OF DAILY LIVING ASSESSMENT; ADVANCED DEMENTIA; AGED; ARTICLE; BEHAVIOR ASSESSMENT; CROSS-SECTIONAL STUDY; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DRUG COST; DRUG THERAPY; FEEDING APPARATUS; FEMALE; HOSPICE CARE; HUMAN; HYPERTENSION; LONG TERM CARE; MALE; MEDICAL ORDER; NOSE FEEDING; NURSING HOME PATIENT; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT RESPONSE; VERY ELDERLY; ECONOMICS; HEALTH SERVICE; INAPPROPRIATE PRESCRIBING; NURSING HOME; STATISTICS AND NUMERICAL DATA; TERMINAL CARE;

AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DEMENTIA; FEMALE; HEALTH SERVICES MISUSE; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; NURSING HOMES; TERMINAL CARE;

EID: 84919605025     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.6040     Document Type: Erratum

References (54)

1. Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med. 2009;361(16):1529-1538.
2. Tjia J, Rothman MR, Kiely DK, et al. Daily medication use in nursing home residents with advanced dementia. J Am Geriatr Soc. 2010;58(5):880-888.
3. Blass DM, Black BS, Phillips H, et al. Medication use in nursing home residents with advanced dementia. Int J Geriatr Psychiatry. 2008;23(5):490-496.
4. Currow DC, Stevenson JP, Abernethy AP, Plummer J, Shelby-James TM. Prescribing in palliative care as death approaches. J Am Geriatr Soc. 2007;55(4):590-595.
5. Luchins DJ, Hanrahan P. What is appropriate health care for end-stage dementia? J Am Geriatr Soc. 1993;41(1):25-30.
6. Introduction. In: Field MJ, Cassel CK, eds; Committee on Care at the End of Life, Institute of Medicine. Approaching Death: Improving Care at the End of Life. Washington, DC: National Academy Press; 1998.
7. Holmes HM, Sachs GA, Shega JW, Hougham GW, Cox Hayley D, Dale W. Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use. J Am Geriatr Soc. 2008;56(7):1306-1311.
8. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605-609.
9. Weschules DJ, Maxwell TL, Shega JW. Acetylcholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use among hospice enrollees with a primary diagnosis of dementia. J Palliat Med. 2008;11(5):738-745.
10. Parsons C, Briesacher BA, Givens JL, Chen Y, Tjia J. Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia. J Am Geriatr Soc. 2011;59(7):1253-1259.
11. Briesacher BA, Soumerai SB, Field TS, Fouayzi H, Gurwitz JH. Medicare Part D's exclusion of benzodiazepines and fracture risk in nursing homes. Arch Intern Med. 2010;170(8):693-698.
12. Research Department American Health Care Association (AHCA). OSCAR data report: nursing facility patient characteristics report. http://www.ahcancal.org/ research-data/oscar-data/NursingFacilityPatientCharacteristics/HISTORICAL-HSNF-OSCAR%20Data%20Report-2006Q2.pdf. Accessed January 26, 2013.
13. Mor V. A comprehensive clinical assessment tool to inform policy and practice: applications of the Minimum Data Set. Med Care. 2004;42(4)(suppl):III50-III59.
14. Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170(1):89-95.
15. Briesacher BA, Tjia J, Field T, Peterson D, Gurwitz JH. Antipsychotic use among nursing home residents. JAMA. 2013;309(5):440-442.
16. Hawes C, Phillips CD, Mor V, Fries BE, Morris JN. MDS data should be used for research. Gerontologist. 1992;32(4):563-564.
17. Hartmaier SL, Sloane PD, Guess HA, Koch GG. The MDS Cognition Scale: a valid instrument for identifying and staging nursing home residents with dementia using the Minimum Data Set. J Am Geriatr Soc. 1994;42(11):1173-1179.
18. Morris JN, Fries BE, Mehr DR, et al. MDS Cognitive Performance Scale. J Gerontol. 1994;49 (4):M174-M182.
19. Assistant Secretary for Planning and Evaluation, Office of Disability, Aging and Long-Term Care Policy, US Department of Health and Human Services. Hospitalizations of nursing home residents. http://aspe.hhs.gov/daltcp/reports/2011/NHResHosp.pdf. Accessed February 19, 2014.
20. Doshi JA, Shaffer T, Briesacher BA. National estimates of medication use in nursing homes: findings from the 1997 Medicare Current Beneficiary Survey and the 1996 Medical Expenditure Survey. J Am Geriatr Soc. 2005;53(3):438-443.
21. Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, Bernabei R. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry. 2003;64(9):1106-1112.
22. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc. 2003;51(9):1305-1317.
23. Mitchell SL, Miller SC, Teno JM, Kiely DK, Davis RB, Shaffer ML. Prediction of 6-month survival of nursing home residents with advanced dementia using ADEPT vs hospice eligibility guidelines. JAMA. 2010;304(17):1929-1935.
24. Red Book. Greenwood Village, CO: Thomson Reuters; 2010. http://www.redbook.com/redbook/awp/. Accessed November 19, 2012.
25. US Department of Health and Human Services, Office of Inspector General. Medicaid's Use of Revised Average Wholesale Prices. Washington, DC: US Department of Health and Human Services; 2001.
26. Brauner DJ, Muir JC, Sachs GA. Treating nondementia illnesses in patients with dementia. JAMA. 2000;283(24):3230-3235.
27. Laroche ML, Perault-Pochat M-C, Ingrand I, et al French Centres of Pharmacovigilance Network. Adverse drug reactions in patients with Alzheimer's disease and related dementia in France. Pharmacoepidemiol Drug Saf. 2013;22(9):952-960.
28. Ganjavi H, Herrmann N, Rochon PA, et al. Adverse drug events in cognitively impaired elderly patients. Dement Geriatr Cogn Disord. 2007;23(6):395-400.
29. Nourhashémi F, Andrieu S, Sastres N, et al. Descriptive analysis of emergency hospital admissions of patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2001;15(1):21-25.
30. Tjia J, Field TS, Mazor KM, et al. Dementia and risk of adverse warfarin-related events in the nursing home setting. Am J Geriatr Pharmacother. 2012;10(5):323-330.
31. McCormick WC, Kukull WA, van Belle G, Bowen JD, Teri L, Larson EB. Symptom patterns and comorbidity in the early stages of Alzheimer's disease. J Am Geriatr Soc. 1994;42(5):517-521.
32. Onder G, Gambassi G, Scales CJ, et al. Adverse drug reactions and cognitive function among hospitalized older adults. Eur J Clin Pharmacol. 2002;58(5):371-377.
33. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003;51(7):937-944.
34. Moyer VA; US Preventive Services Task Force. Screening for cognitive impairment in older adults: US Preventive Services task force recommendation statement. Ann Intern Med. 2014;160(11):791-797. doi:10.7326/M14-0496.
35. Shega JW, Ellner L, Lau DT, Maxwell TL. Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors. J Palliat Med. 2009;12(9):779-783.
36. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-324.
37. Winblad B, Kilander L, Eriksson S, et al Severe Alzheimer's Disease Study Group. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367(9516):1057-1065.
38. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14(2):135-146.
39. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012;366(10):893-903.
40. Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life. Drugs Aging. 2010;27(6):435-449.
41. Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore DD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother. 2009;7(2):74-83.
42. Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169(9):867-873.
43. Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165(7):808-813.
44. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011;10(3):373-387.
45. US Food and Drug Administration. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed January 15, 2013.
46. Gozalo P, Teno JM, Mitchell SL, et al. End-of-life transitions among nursing home residents with cognitive issues. N Engl J Med. 2011;365(13):1212-1221.
47. Mitchell SL, Teno JM, Roy J, Kabumoto G, Mor V. Clinical and organizational factors associated with feeding tube use among nursing home residents with advanced cognitive impairment. JAMA. 2003;290(1):73-80.
48. Gessert CE, Haller IV, Johnson BP. Regional variation in care at the end of life. BMC Geriatr. 2013;13:39. doi:10.1186/1471-2318-13-39.
49. Goodman DC, Esty AR, Fisher ES, Chang CH. Trends and variation in end-of-life care for Medicare beneficiaries with severe chronic illness: a report of the Dartmouth Atlas Project. www.dartmouthatlas.org/downloads/reports/ EOL-Trend-Report-0411.pdf. Accessed May 27, 2014.
50. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616-631. doi: 10.1111/j.1532-5415.2012.03923.x.
51. Geldmacher DS. Cost-effectiveness of drug therapies for Alzheimer's disease: a brief review. Neuropsychiatr Dis Treat. 2008;4(3):549-555.
52. Simoni-Wastila L, Shaffer T, Stuart B; US Department of Health and Human Services. National estimates of prescription drug utilization and expenditures in long-term care facilities. http://aspe.hhs.gov/daltcp/ reports/2006/pdnatest.pdf. Accessed February 19, 2014.
53. Sisko AM, Truffer CJ, Keehan SP, Poisal JA, Clemens MK, Madison AJ. National health spending projections. Health Aff (Millwood). 2010;29(10):1933-1941.
54. Omnibus Budget Reconciliation Act of 1987, OBRA-87, Public Law No. 100-203 Subtitle C: Nursing Home Reform, F329 Unnecessary drugs. 100th Cong (1987).